BTLA Protein, Human, Recombinant (hFc Tag): Product Information
> 90 % as determined by SDS-PAGE
< 1.0 EU per μg of the protein as determined by the LAL method
1.Measured by its binding ability in a functional ELISA. 2.Immobilized human BTLA-Fc (Cat:11895-H02H) at 10μg/mL (100μL/well) can bind biotinylated mouse HVEM-Fch (Cat:10567-M03S), the EC50 of biotinylated mouse HVEM-Fch is 6-70ng/mL.
A DNA sequence encoding the human BTLA (NP_001078826.1) (Met1-Thr134) was expressed with the Fc region of human IgG1 at the C-terminus.
The recombinant human BTLA comprises 342 amino acids and has a predicted molecular mass 38.8 kDa. As a result of glycosylation, it migrates as an approximately 53.7 kDa band in SDS-PAGE under reducing conditions.
Lyophilized from sterile PBS, pH 7.4. Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃ Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
Measured by its binding ability in a functional ELISA. Immobilized human BTLA-Fc (Cat: 11895-H02H) at 10μg/mL (100μL/well) can bind biotinylated mouse HVEM-Fch (Cat: 10567-M03S), the EC50 of biotinylated mouse HVEM-Fch is 6-70 ng/mL.
BTLA is a inhibitory molecule which belongs to the Ig superfamily. It down-modulates immune responses. As such, reagents that regulate the binding of BTLA to its ligand or alter BTLA signaling have significant therapeutic promise. BTLA is crucial to understand the mechanism(s) of action of these antibodies before attempting clinical applications. BTLA is not expressed by naive T cells, but it is induced during activation and remains expressed on T helper type 1 (T(H)1) but not T(H)2 cells. BTLA is a third inhibitory receptor on T lymphocytes with similarities to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1).
Fourcade J, et al. (2012) CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 72(4):887-96.
Kojima R, et al. (2011) Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT. J Mol Biol. 413(4):762-72.
Oki M, et al. (2011) A functional polymorphism in B and T lymphocyte attenuator is associated with susceptibility to rheumatoid arthritis. Clin Dev Immunol. 305656.
Add to Cart SuccessfullyAdd to Cart FailedShopping cart is being updated, please waitU.S.A.
Successfully added to cart Please enter catalog numberSubmitted successfullyNetwork ErrorPlease enter your company namePlease enter your namePlease enter your emailPlease enter a valid email addressPlease enter some messageNot found.